Latest Scottish Medicines Consortium decisions

The Scottish Medicines Consortium (SMC) has accepted the following drugs for use in NHS Scotland:

  • Eslicarbazepine acetate (Zebinix), as adjunctive therapy for adults with partial-onset seizures. Use is restricted to patients with highly refractory epilepsy who have been heavily pre-treated and remain uncontrolled on existing antiepileptic drugs.
  • Oxycodone hydrochloride 50mg/ml injection (OxyNorm), for the treatment of moderate to severe cancer pain. Use is restricted to patients who have difficulty tolerating morphine or diamorphine and who require a high dose of oxycodone delivered via syringe pump which would necessitate the daily preparation of an additional syringe pump if oxycodone 10mg/ml were used.

Following full submissions to SMC, the following drugs were rejected for use in NHS Scotland:

  • Eculizumab (Soliris), for paroxysmal nocturnal haemoglobinuria
  • Glucosamine sulphate (Glusartel), for mild to moderate osteoarthritis of the knee
  • Sevelamer carbonate (Renvela), for hyperphosphataemia in adults on dialysis
  • Trabectedin (Yondelis), for advanced soft tissue sarcoma in patients who are unresponsive to or unsuitable for anthracyclines and ifosfamide

In the absence of submissions to the SMC, the following drugs cannot be recommended for use in NHS Scotland:

  • Amifampridine (Firdapse), for Lambert-Eaton myasthenic syndrome
  • Canakinumab (Ilaris), for cryopyrin-associated periodic syndromes
  • Docetaxel (Taxotere), for the adjuvant treatment of operable node-negative breast cancer
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)